PTPRC and adenocarcinoma: To our knowledge, we are the first to report the effects of FOXP3 targeting on intratumoral Treg in clinical samples from patients with adenocarcinoma, melanoma, mesothelioma and squamous cell carcinoma, and we showed a 65% decrease on average of Treg mRNA and a 60% decrease of Treg numbers in the CD45+ subset.